Sera Prognostics (SERA) Q4 2025 earnings review
Landmark Clinical Validation Achieved, But Commercial Reality Remains Pre-Revenue
Sera Prognostics exits 2025 having secured its most critical clinical milestone, but remains an effectively pre-revenue company. The January 2026 publication of the PRIME study validates the PreTRM test's ability to reduce NICU admissions by 20%, shifting the company's narrative entirely to commercial execution. Operating expenses are stable at ~$9 million per quarter, and a cash balance of $95.8 million extends the runway through 2028. However, the glacial pace of payer adoption and negligible Q4 revenue of just $10,000 highlight the massive execution gap between clinical success and financial sustainability.
🐂 Bull Case
The peer-reviewed publication of the 5,018-patient PRIME study provides the definitive clinical evidence required to unlock payer coverage and guideline inclusion discussions.
Following a successful $57.5M raise in Q1 2025, the company has $95.8M in liquidity, providing a stable runway through 2028 to execute its commercial strategy without immediate dilution risk.
🐻 Bear Case
Despite expanding the sales force and engaging with multiple payers, revenue actually declined YoY to a negligible $10,000 in Q4, underscoring the extreme difficulty of monetizing new diagnostics.
The timeline to convert Medicaid pilot programs into statewide coverage routinely exceeds 24 months, delaying any meaningful revenue inflection.
⚖️ Verdict: ⚪
Neutral. The foundational pieces are in place: peer-reviewed clinical data, an expanded sales team, and a strong balance sheet. However, the absolute lack of current revenue makes this an execution-only story heavily exposed to long healthcare adoption cycles.
Key Themes
PRIME Study Publication Triggers Next Phase
The January 2026 publication of the PRIME study in the PREGNANCY journal is an accelerating driver for the company's entire business model. The data confirms the PreTRM test drives a 56% reduction in babies born before 32 weeks, a 20% reduction in NICU admissions, and requires a Number Needed to Screen (NNS) of only 4.2 to save one NICU day. This specific health-economic data is the primary weapon for the newly expanded sales force to negotiate payer contracts.
Commercial Infrastructure Expansion
The company is accelerating its transition from an R&D organization to a commercial entity. Sera added six field sales staff in Q4 and previously appointed a new Chief Commercial Officer and Chief Medical Officer. Discussions are actively advancing with 10 commercial and Medicaid payers across 13 target states. This footprint expansion is necessary to capitalize on the PRIME publication.
Negligible Revenue Contradicts Commercial Progress
Despite management's positive narrative regarding payer engagement and expanded commercial teams, Q4 2025 revenue was $10,000, decelerating from $24,000 a year ago. Operating expenses for the quarter were $9.0 million. This specific juxtaposition highlights a stark concern: the company is currently burning roughly $900 for every $1 it generates, and pilot program traction has yet to yield tangible financial results.
Glacial Payer Adoption Cycles
The structural reality of the U.S. healthcare macro environment is a major headwind. Management has previously noted that the path from initial Medicaid engagement to state coverage can take 24 months or longer. Furthermore, formal inclusion into the American College of Obstetricians and Gynecologists (ACOG) guidelines—the ultimate catalyst for widespread adoption—is historically a multi-year process.
Expense Reallocation: R&D Yields to SG&A
A stable, deliberate shift in the company's cost structure is underway. For the full year 2025, R&D expenses decelerated to $13.2 million (down from $14.7 million in 2024) due to the completion of the PRIME study. Conversely, SG&A accelerated to $23.3 million (up from $21.9 million) to fund commercialization efforts. This mix shift will likely continue as the company chases revenue growth.
European CE Mark Pursuit
Sera is advancing regulatory preparations to secure a CE mark for the PreTRM Global Test. Recent expert commentary in European journals highlighted the test's cost-effectiveness as well-suited for publicly funded European healthcare systems. This represents a potentially massive secondary market, though it requires a decentralized immunoassay model rather than the US centralized lab approach.
Other KPIs
Stable compared to the $32.9 million net loss in 2024. The company has successfully controlled its cash burn during the transition year, reallocating savings from clinical trials directly into its commercial sales expansion without blowing out the total expense base.
Cash, cash equivalents, and available-for-sale securities ended the year at a robust level, driven by the $57.5 million gross proceeds from the February 2025 follow-on offering. This balance sheet strength is the company's strongest asset while it awaits revenue generation.
Guidance
Stable. Management reiterated that current capital resources will fund operations through 2028. This assumes continued strict cost controls and covers significant planned commercial and adoption milestones. The company did not provide specific revenue guidance.
Key Questions
Medicaid Pilot Conversions
With 10 payers in discussions across 13 states, what specific milestones or timelines must be met to convert these early pilots into state-wide, revenue-generating contracts in 2026?
ACOG Guideline Strategy
Following the publication of the PRIME study, what is your realistic expectation for the timing of an ACOG guideline review, and what interim clinical data will you submit to accelerate that process?
European Commercialization Costs
As you pursue CE marking for the PreTRM Global Test, how much of the $95.8 million cash runway is allocated specifically for the European regulatory and commercial launch vs. domestic expansion?